ArticleCureus2025
Tumor Volume Index as a Predictor of Pelvic Lymph Node Metastasis in Low-Risk Endometrial Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify predictors of pelvic lymph node metastasis in low-risk endometrial cancer, defined as cases with no more than half myometrial invasion, preoperative endometrial biopsy results indicating endometrioid carcinoma Grade 1 (G1) or Grade 2 (G2), and no extrauterine spread. Among the factors examined, we focused on the tumor volume index derived from MRI, calculated by multiplying the maximum longitudinal diameter along the uterine axis, the maximum anteroposterior diameter on the sagittal plane, and the maximum transverse diameter on the horizontal plane. A retrospective analysis was conducted on 117 patients who underwent the standard treatment protocol (total hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node dissection) at our institution from July 1, 2014, to December 31, 2023. Pelvic lymph node metastasis was observed in seven cases (5.9%). Univariate analysis showed a significant association with serum cancer antigen-125 (CA-125) level (p=0.035) and tumor volume index (p=0.003). A receiver operating characteristic (ROC) analysis revealed that a tumor volume index cutoff of 38 cm³ yielded an area under the curve (AUC) of 0.83, with a true positive fraction (TPF) of 0.86 and a false positive fraction (FPF) of 0.15. Multivariate analysis also identified a tumor volume index (≥38 cm³) as an independent predictive factor (odds ratio 26.3, 95% confidence interval 2.6-272, p=0.006). Cases with a tumor volume index ≥38 cm³ accounted for 23 cases (20% of all) of the cohort; among these, six cases (25%) had pelvic lymph node metastases. In contrast, the metastasis rate was only one case (1%) in 94 cases (80% of all) with a tumor volume index <38 cm³. These findings suggest that the tumor volume index is useful for evaluating the risk of pelvic lymph node metastasis in low-risk endometrial cancer, contributing to decision-making on whether to perform pelvic lymph node dissection and risk stratification for sentinel lymph node navigation surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.